|drug2731||Questionnaire : Preparedness for Caregiving Scale Wiki||0.71|
|drug4032||quality of life questionnaires Wiki||0.71|
|D012127||Respiratory Distress Syndrome, Newborn NIH||0.06|
|D055371||Acute Lung Injury NIH||0.06|
|D012128||Respiratory Distress Syndrome, Adult NIH||0.05|
There are 2 clinical trials
In this study, the investigators are attempting to evaluate the influence of socio-economic factors on the functional recovery (physical and psychological) of patients who developed ARDS after a COVID-19 infection, with the aim of offering personalized medical and social follow-up and support measures in order to avoid medium- and long-term complications, which can result in handicaps, reduced quality of life, and a higher risk of death.
Description: Defined by the presence of at least one of the following : An alteration of the alveolar-capillary diffusion of CO <80% of the predicted normal values And/or a forced vital capacity <80% of predicted normal values and/or O2 desaturation in the 6-minute walk test And/or pulmonary parenchymatous disease with fibrosis in tomodensitometry.Measure: Respiratory sequelae 6 months after resuscitation. Time: Through study completion, an average of 6 months
The purpose of this study is to identify behaviours and experiences of communities healthcare professionals (doctors, nurses and physiotherapists) in the management of the SARS-CoV 2 epidemic by identifying the impact of the epidemic on their work, their personal life and the difficulties they had experienced.
Description: The greatest possible diversity of themes extracted during the analysis of interviews. Identifying the impact of the epidemic of healthcare worker, their personal life and the difficulties they had experiencedMeasure: Diversity of themes extracted about care situations management of the COVID-19 epidemic. Time: 1 Day
Description: 8 questions, each evaluated by a 4-level Likert scaleMeasure: Preparedness for caregiving scale (PCS) Time: 1 Day
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports